BioVenture VoiCes with Chris Garabedian
- Folgen
- 51
- Erscheint
- alle zwei Wochen
- Letzte Folge
- 2. Nov. 2026
Über den Podcast
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.
Folgen 51
Episode 51: Vianti Capital's Arjun Goyal
With an immigrant upbringing that took him to Australia, where he practiced medicine, and the UK, where he went to graduate school, before coming to the U.S. for a startup he co-founded and Harvard Business …
Shownotes
With an immigrant upbringing that took him to Australia, where he practiced medicine, and the UK, where he went to graduate school, before coming to the U.S. for a startup he co-founded and Harvard Business School, Arjun Goyal describes learnings along the way. He discusses his extensive experience in the venture world, first at 5AM Ventures and then Vida Ventures, before more recently founding Vianti Capital.
Episode 50: Third Rock Ventures' Bob Tepper
the early days of the biotech sector before it was common, the founding of Third Rock Ventures, and the unique culture at Third Rock that has produced so many investors and company builders who have achieved …
Shownotes
the early days of the biotech sector before it was common, the founding of Third Rock Ventures, and the unique culture at Third Rock that has produced so many investors and company builders who have achieved great things in their careers.
Episode 49: Sanofi Ventures' Jason Hafler
Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of …
Shownotes
Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.
Episode 48: Blackstone's Kiran Reddy
Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience …
Shownotes
Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience, and a stop at Biogen, before returning to investing at Clarus, which was acquired by Blackstone. He recalls the unique opportunity he saw when a company with the resources of Blackstone decided to go big into life sciences.
Episode 47: Ally Bridge's Andrew Lam
Andrew Lam describes his career journey that started with a Doctor of Pharmacy education before working in industry, the investment world, back in industry, and then settling at Ally Bridge. He discusses the …
Shownotes
Andrew Lam describes his career journey that started with a Doctor of Pharmacy education before working in industry, the investment world, back in industry, and then settling at Ally Bridge. He discusses the successful investments Ally Bridge has made in biotech, including in technologies like radiopharmaceuticals and ADCs, and the concept of being a bridge to China innovation.
Episode 46: Catalys Pacific's BT Slingsby
BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from …
Shownotes
BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from Japan and building companies around them internationally., and also in-licensing assets approved elsewhere and doing the clinical work in Japan to get them approved there. Plus, the story of the GHIT Fund, which is meant to bring Japanese innovation to neglected diseases around the world.
Episode 45: Catalio Capital Management's George Petrocheilos
George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life …
Shownotes
George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life sciences investing at Camden Partners, and then co-founding Catalio. Over a short period of time, keys to success have been empowering academics and entrepreneurs and expanding into multiple strategies.
Episode 44: BainCapital's Adam Koppel
Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take …
Shownotes
Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors.
Episode 43: Lightstone Venture's Mike Carusi
Mike Carusi describes his early life and career, how gaining an appreciation for sales made an impression on him early on, and his philosophy of investing in medical devices - and the similarities and …
Shownotes
Mike Carusi describes his early life and career, how gaining an appreciation for sales made an impression on him early on, and his philosophy of investing in medical devices - and the similarities and differences between that and investing in therapeutics.
Episode 42: Nextech's Thilo Schroeder
Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his …
Shownotes
Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.
Episode 41: Forbion's Nanna Lüneborg
Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus …
Shownotes
Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.
Episode 40: GV's Krishna Yeshwant
He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also …
Shownotes
He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also today how Alphabet's scale and cash gives them the ability to ride cycles and make concentrated bets on companies the team has conviction on.
Episode 39: SV Health Investors' Kate Bingham
Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery …
Shownotes
Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.
Episode 38: Deerfield Management's Jason Fuller
He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas …
Shownotes
He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI.
Episode 37: SR One's Simeon George
Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks …
Shownotes
Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks about investing in different indications and modalities.
Episode 36: Sofinnova Invetments' Jim Healy
He discusses learnings from his decades in venture at Sofinnova Investments including 'products vs platform', therapeutics areas of interest, modalities, and how he utilizes board seats and thinks about management teams.
Episode 35: INITIATE Ventures' Jessica Owens
Jessica Owens discusses the many experiences she has had in her career, including working on the venture side at Kleiner Perkins and Versant Ventures and on the operating side at Genomic Health and Grail. She …
Shownotes
Jessica Owens discusses the many experiences she has had in her career, including working on the venture side at Kleiner Perkins and Versant Ventures and on the operating side at Genomic Health and Grail. She highlights the value of VCs being able to understand how operators like CEOs think, and describes the type of investing INITIATE focuses on.
Episode 34: General Atlantic's Brett Zbar
Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between …
Shownotes
Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between private equity and venture capital, and discusses which themes in biotech and healthcare appeal to him today.
Episode 33: Pappas Capital's Art Pappas
Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how …
Shownotes
Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how having corporates partners as LPs and co-investors has been a recipe for success.
Episode 32: ARCH Venture Partners' Bob Nelsen
While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to …
Shownotes
While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry.
Episode 31: Polaris Partners' Amy Schulman
She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses …
Shownotes
She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.
Episode 30: F-Prime Capital Senior Managing Partner Stephen Knight
He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to …
Shownotes
He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to focus on life sciences in its early days, and F-Prime's investing philosophy today.
Episode 29: Averin Managing Partner David Berry
He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of …
Shownotes
He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.
Episode 28: Hatteras Venture Partners' Clay Thorp
Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in …
Shownotes
Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders.
Episode 27: Avalon Bioventures' Jay Lichter
Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he …
Shownotes
Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures.
Episode 26: venBio's Corey Goodman
Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is …
Shownotes
Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is thankful that he has experienced these different components of life sciences.
Episode 25: Atlas Venture's Bruce Booth
Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more.
Episode 24: Samsara Biocapital's Srini Akkaraju
The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses …
Shownotes
The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses how the firm invests in all stages of life sciences companies and why he believes patience is a key virtue.
Episode 23: a16z's Vineeta Agarwala
Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks …
Shownotes
Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks about a16z's investment philosophy of "providing more than just a check," and a recent $500M fund partnered with Lilly.
Episode 22: Adjuvant Capital's Glenn Rockman
Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for …
Shownotes
Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for public good ultimately sparked Adjuvant Capital in 2019. Armed with a $300M+ fund that was raised from numerous foundations and for-profit funds in 2021, Adjuvant has been investing in public health technologies, post proof of concept, to help accelerate their development and ultimately make them more accessible to those around the world who need them.
Hier stehen die neuesten 40 von 51 Folgen. Ältere Folgen findest du im Feed des Podcasts.
Ähnliche Podcasts
Mehr Wissenschaft-Podcasts
Ist das dein Podcast?
Bestätige es mit einem Eintrag in deinem Feed: Du bekommst hier einen Code, trägst ihn als podcast:txt in den Kanal deines Feeds ein, und wir prüfen ihn. Danach steht dein Podcast als „verifiziert“ bei SoundNode.